Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Buys 6,000 Shares

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. acquired 6,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were purchased at an average price of $2.59 per share, with a total value of $15,540.00. Following the completion of the acquisition, the director now owns 928,334 shares in the company, valued at approximately $2,404,385.06. The trade was a 0.65 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Anixa Biosciences Trading Up 5.7 %

NASDAQ:ANIX opened at $2.97 on Thursday. The firm’s fifty day simple moving average is $2.77 and its 200 day simple moving average is $3.04. Anixa Biosciences, Inc. has a twelve month low of $2.07 and a twelve month high of $5.00. The firm has a market capitalization of $95.63 million, a price-to-earnings ratio of -7.62 and a beta of 0.90.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. On average, analysts predict that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of ANIX. Tyler Stone Wealth Management grew its position in Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after acquiring an additional 21,008 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares in the last quarter. Westside Investment Management Inc. boosted its stake in shares of Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares during the period. Finally, Virtu Financial LLC acquired a new stake in Anixa Biosciences during the 3rd quarter valued at $34,000. 29.13% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Anixa Biosciences in a research report on Tuesday, November 19th. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a report on Wednesday.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.